EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

LIM kinases in cardiovascular health and disease

Olubodun M Lateef, Christopher Foote, Gavin Power, Camila Manrique-Acevedo, Jaume Padilla, Luis A Martinez-Lemus

Frontiers in Physiology · 18.12.2024 · 15

DOI: 10.3389/fphys.2024.1506356 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Physiology, online erschienen am 18.12.2024. Verfasst von Olubodun M Lateef und 5 weiteren Autor:innen. Beteiligte Einrichtung: NextGen Precision Health, University of Missouri, Columbia, MO, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Lim Kinase (LIMK) family of serine/threonine kinases is comprised of LIMK1 and LIMK2, which are central regulators of cytoskeletal dynamics via their well-characterized roles in promoting actin polymerization and destabilizing the cellular microtubular network. The LIMKs have been demonstrated to modulate several fundamental physiological processes, including cell cycle progression, cell motility and migration, and cell differentiation. These processes play important roles in maintaining cardiovascular health. However, LIMK activity in healthy and pathological states of the cardiovascular system is poorly characterized. This review highlights the cellular and molecular mechanisms involved in LIMK activation and inactivation, examining its roles in the pathophysiology of vascular and cardiac diseases such as hypertension, aneurysm, atrial fibrillation, and valvular heart disease. It addresses the LIMKs’ involvement in processes that support cardiovascular health, including vasculogenesis, angiogenesis, and endothelial mechanotransduction. The review also features how LIMK activity participates in endothelial cell, vascular smooth muscle cell, and cardiomyocyte physiology and its implications in pathological states. A few recent preclinical studies demonstrate the therapeutic potential of LIMK inhibition. We conclude by proposing that future research should focus on the potential clinical relevance of LIMK inhibitors as therapeutic agents to reduce the burden of cardiovascular disease and improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

arterial stiffeningatherosclerosisatrial fibrillationcardiovascular diseasehypertensionvascular remodeling

Autor:innen und Institutionen

  • NextGen Precision Health, University of Missouri, Columbia, MO, United States.
  • Department of Medical Pharmacology and Physiology, University of Missouri Columbia, Columbia, MO, United States.
  • Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States.
  • Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States.
  • Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Columbia, MO, United States.
  • Center for Precision Medicine, Department of Medicine, University of Missouri, Columbia, MO, United States.

Förderung

  • NIA NIH HHS

Zitieren

APA

Lateef, O. M., Foote, C., Power, G., Manrique-Acevedo, C., Padilla, J., & Martinez-Lemus, L. A. (2024). LIM kinases in cardiovascular health and disease. Frontiers in Physiology, 15. https://doi.org/10.3389/fphys.2024.1506356

Vancouver

Lateef OM, Foote C, Power G, Manrique-Acevedo C, Padilla J, Martinez-Lemus LA. LIM kinases in cardiovascular health and disease. Frontiers in Physiology. 2024;15. doi:10.3389/fphys.2024.1506356

BibTeX
@article{Lateef2024,
  author = {Lateef, Olubodun M and Foote, Christopher and Power, Gavin and Manrique-Acevedo, Camila and Padilla, Jaume and Martinez-Lemus, Luis A},
  title = {LIM kinases in cardiovascular health and disease},
  journal = {Frontiers in Physiology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphys.2024.1506356}
}
Kostenlos starten →